RVL Pharmaceuticals plc (RVLPQ)

OTCMKTS · Delayed Price · Currency is USD

0.000001

0.00 (0.00%)

At close: Aug 14, 2026

-99.00% (1Y)

Market Cap	111.00 -99.0%
Revenue (ttm)	36.92M +5.6%
Net Income	-68.27M
EPS	-0.70
Shares Out	111.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	359
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	n/a
Beta	43.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and chan... [Read more]

Industry Biotechnology

Sector Healthcare

CEO Brian Markison

Employees 125

Stock Exchange OTCMKTS

Ticker Symbol RVLPQ

Full Company Profile